Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Long term

<< Previous

Bullboard Posts

Next >>

Comment by Ryeman40on Dec 11, 2020 1:29pm

202 Views

Post# 32089372

RE:RE:Long term

All the good points i got from interview
13:30 Dan says if you solve problem with nsaid safety the drug is worth 30billion lifetime
20:00 Dr. Stauffer was actually involved in developing opioids
21:15 Their "unknown university" has one of the best chemists in H2S and working on different indications and fresh ip's
32:40 After foray into US institutional investors meetings first part of winter look into uplist
38:00 Lol Dan's comment on being public ceo and watching what he has to say but their safety was 1500% better. Superb results.
38:50 Dr. Stauffer bought on open market. Put his money where his mouth is lol.
42:30 Dr. Stauffer expects 150 mg to hit statistical significant efficacy when powered to do so in trial.
58:50 Filing IND after Christmas and also another study underway called absorption, metabolism, and excretion which will be longer than 2 weeks. More data under their belt going forward and also metion 90% of americans take NSAID.
1:01:40 About another 60million for duration of trials either dilution or partner.
1:06:30 Already thinking about other indications like cardiology and alzheimer's. Revolves around inflammation.
1:12:00 This one is big in my books but they have a good relationship with fda (thanks Joe!) and they had very good advice from them that they took and it worked in their favor.
1:24:00 Engineer another drug from their chemist at said university for rare diseases.
Once first drug is approved and i think it's almost guaranteed since efficacy will be there and most of it will hinge on the safety aspect, this will be nothing but a cash cow with future indications
This really is what you look for when buying into biotech. Safety second to none. Efficacy the same or better. And future ip's as far as you can see.
Most traders won't like this because i don't think price will appreciate for awhile (but who knows with markets these days) but investors love this because they see value well into the future especially being so undervalued at the moment.